Navigation Links
Gene variation affects tamoxifen's benefit for breast cancer

One of the most commonly prescribed drugs for breast cancer, tamoxifen, may not be as effective for women who inherit a common genetic variation, according to researchers at the University of Michigan and the Mayo Clinic. The genetic variation affects the level of a crucial enzyme that activates tamoxifen to fight breast cancer.

The study, co-led by researcher James Rae, Ph.D., at the University of Michigan Comprehensive Cancer Center and Matthew Goetz, M.D., an oncologist at the Mayo Clinic, tested the most common genetic variant responsible for lowering the CYP2D6 enzyme, and found that women with this genetic variant were almost twice as likely to see their breast cancer return. Up to 10 percent of women inherit this genetic trait.

Their findings are published in the Dec. 20 issue of The Journal of Clinical Oncology.

"Our group has shown that CYP2D6 is responsible for activating tamoxifen to a metabolite called endoxifen that is nearly 100 times more potent as an anti-estrogen than tamoxifen itself," says Rae, research assistant professor of internal medicine at the U-M Medical School. "Our study suggests that women who inherit a genetic variant in the CYP2D6 gene appear to be at higher risk of relapse when treated with five years of tamoxifen."

Researchers at the U-M Comprehensive Cancer Center were among the group to discover CYP2D6 metabolizes tamoxifen, and they are leading ongoing work looking at how genetic differences affect women's response to tamoxifen. Their research has also found the antidepressant drug Paxil can prevent tamoxifen from being activated, while the antidepressant drug Effexor does not. These drugs, selective serotonin reuptake inhibitors or SSRI's, are often used to treat hot flashes, a common side effect of tamoxifen.

In this current study of 256 women with breast cancer, researchers also found that women with the CYP2D6 variant were less likely to have hot flashes. Any hot flashes among this group
'"/>

Source:University of Michigan Health System


Page: 1 2

Related biology news :

1. Gene variations explain drug dose required to control seizures
2. Survival of heart patients on beta-blockers varies greatly with genetic variation
3. Genetic variation alters response to common anti-clotting drug
4. Studies on human genome variation provide insight into disease
5. New discovery: Molecular variation in one gene affects the growth of natural populations
6. Researchers map of genetic variations implicated in disease
7. Gene variation increases SIDS risk in African Americans
8. Chimpanzee study reveals genome variation hotspots
9. A new kind of mutation could explain numerous phenotypic variations in various species
10. International team analyzes human genetic variation in key immune region
11. New technology used to construct the first map of structural variation in the human genome
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene variation affects tamoxifen benefit for breast cancer

(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
(Date:3/23/2015)... 2015 SoundView Technology Group issues a new research ... ) Wocket smart wallet. SoundView was one of the selected user ... with the Wocket in multiple scenarios and outlets. ... other retailers, making both debit and credit card payments.  ... "If the company meets their plans in 2015, it would ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... Wistar Institute have deciphered the structure of the active ... role in the development of nearly all human cancers. ... of new, broadly effective cancer drugs, as well as ... a decade to find drugs that shut down telomerasewidely ...
... have long known to be related to each other women ... Now, a master switch has been found in the brain of ... Biological Studies say it may work the same way in humans. ... Aug. 31 online edition of Nature Medicine , suggest that ...
... was reached by the Alliance for a Healthier Generation ... on "competitive foods" such as soft drinks at schools. ... the availability of soft drinks at school may not ... children. In a study of more than 4,000 ...
Cached Biology News:Landmark study opens door to new cancer, aging treatments 2Landmark study opens door to new cancer, aging treatments 3New master switch found in the brain that regulates appetite and reproduction 2New master switch found in the brain that regulates appetite and reproduction 3New master switch found in the brain that regulates appetite and reproduction 4
(Date:4/17/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: ... develops and commercializes proprietary technologies and products for ... has received approval from the TSX Venture Exchange ... share purchase warrants ("the Warrants") of the Company, ... May 2013 private placement financing. Each ...
(Date:4/17/2015)... BellBrook Labs announced today that ... the powerful Orthogonal Pooled Screening (OPS) Platform developed ... the Lankenau Institute for Medical Research (LCGC) in ... improve successful drug discovery outcomes using far more ... libraries available nowhere else, coupled to a state-of-the-art ...
(Date:4/16/2015)... April 16, 2015 Capillus, LLC ... and physician network in Europe and Asia. The ... appointed Fernando Bermúdez, former Business Development Director of ... industry veteran, Mr. Bermúdez’s professional achievements include increasing ... Spain, while also penetrating the Portuguese marketplace with ...
(Date:4/16/2015)... OncoTAb, Inc., a University ... company, announced today the appointment of physician and ... Operating Officer (COO). Cooper brings to OncoTAb more ... diagnostic and biotechnology platforms in the fields of ... career transcends the field of medical and scientific ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2OncoTAb Names Dr. David L. Cooper as COO 2
... Antidepressant Can Help Adults Living With ... Relief -(1), PRINCETON, N.J. and TOKYO, Nov. ... and Otsuka Pharmaceutical Co.,Ltd. announced today that the ... New Drug Application for ABILIFY(R),(aripiprazole) as adjunctive, or ...
... BB: CLBE), an emerging life sciences company ( http://www.CalbaTech.com ... stem cells for,possible future therapeutic uses and providing products ... to academic,institutions, said today in its 10Q filing with ... be profitable in 2007. The addition of sales ...
... will present at the Piper Jaffray 19th Annual Healthcare ... Pierre Hotel in New York. John L.,Bishop, Chief Executive ... Chief Financial Officer, will provide a corporate overview. ... be,accessed on Cepheid,s Web site at http://www.cepheid.com ...
Cached Biology Technology:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 2U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 3U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 4U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 5U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 6U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 7U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 8U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD) 9CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007 2CalbaTech Files Nine Month Financial Results; Anticipates Profitability in 2007 3Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference 2
... Topo I, Wild Type ... Tris-HCl, 1 mM DTT, 200 µM EDTA, 20% ... topoisomerase I (Topo I) is a monomeric protein ... gene. It catalyzes the relaxation of both positive ...
RNase-Free DNase 50 l...
Request Info...
... is a DNA-dependent RNA polymerase which is ... It efficiently synthesizes in vitro transcripts from ... from a T7 promoter. Transcripts can ... in vitro translation, substrates in RNA processing ...
Biology Products: